Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 11/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAF1 | P04049 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1729397 | 0.94 | F2R (0.53) | F2R | |
| Trifluoroacetic Acid SCHEMBL1730888 | 0.94 | F2R (0.52) | F2R | |
| Bromide SCHEMBL1731007 | 0.91 | F2R (0.65) | F2RALDH1A1L3MBTL1SMN1; SMN2GAA | |
| SCHEMBL1729578 | 0.91 | F2R (0.56) | F2RALDH1A1L3MBTL1SMN1; SMN2BRAF | |
| Trifluoroacetic Acid SCHEMBL1729309 | 0.91 | F2R (0.55) | F2RALDH1A1L3MBTL1SMN1; SMN2BRAF | |
| SCHEMBL1729310 | 0.90 | F2R (0.60) | F2RALDH1A1L3MBTL1SMN1; SMN2BRAF | |
| Bromide SCHEMBL5487273 | 0.90 | F2R (0.53) | F2RMAPT | |
| SCHEMBL14449142 | 0.89 | F2R (0.69) | F2RALDH1A1L3MBTL1SMN1; SMN2GAA | |
| Trifluoroacetic Acid SCHEMBL1729913 | 0.89 | F2R (0.47) | F2R | |
| Bromide SCHEMBL1729157 | 0.89 | F2R (0.69) | F2RALDH1A1L3MBTL1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2290/4885ALDH1A1 443/4885L3MBTL1 3538/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2289/4885ALDH1A1 437/4885L3MBTL1 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.